RecruitingNCT06811935

PEDI Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcus Study

Feasibility of a Study to Determine the Incidence and Natural History of Children With Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)


Sponsor

University of Wisconsin, Madison

Enrollment

30 participants

Start Date

Feb 17, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The objective of the Pediatric Epidemiological Data and Incidence (PEDI) PANDAS study is to demonstrate the feasibility of enrollment and retention of subjects in a study to determine the incidence and natural history of children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) with regard to spectrum, course and outcome. The investigators aim to demonstrate they can recruit and retain 85% of children who are eligible for this study. Eligible children are those who fit criteria for PANS and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (PANDAS). Each child will be followed for one year.


Eligibility

Min Age: 3 YearsMax Age: 17 Years

Inclusion Criteria23

  • Child age 3-17 years old
  • Child and their parent/guardian are able to complete all study activities in English
  • Potential participant's family plans to be followed within UW Health or Dartmouth Health for at least one year
  • Pediatric patient who is a current member of the primary care population at either UW Health or Dartmouth Health
  • Abrupt onset of symptoms (within 7 days) occurring in the past 3 months. Willing to come in-person for at least the baseline visit.
  • Suspected diagnosis of PANS or PANDAS based on published criteria:
  • PANS: (A) Abrupt, dramatic, overnight onset of obsessive compulsive disorder (OCD) or severely restricted food intake; (B) concurrent abrupt onset of additional severe neuropsychiatric symptoms from at least 2 of the following 7 categories:
  • Anxiety
  • Emotional lability and/or depression
  • Irritability, aggression and/or severe oppositional behaviors
  • Developmental regression
  • Deterioration in school performance
  • Sensory or motor abnormalities, including heightened sensitivity to sensory stimuli, hallucinations, dysgraphia, complex motor, and/or vocal tics
  • Somatic signs and symptoms, including sleep disturbances, enuresis or urinary frequency consistent with a known neurologic or medical disorder.
  • AND (C) symptoms not better explained by another medical or neurologic disorder
  • PANDAS
  • Presence of OCD and/or tic disorder
  • Pre-pubertal onset of symptoms (i.e., 3-12 years old)
  • Episodic course characterized by very acute and severe onset and dramatic symptom exacerbations
  • Neurologic abnormalities present during symptom exacerbations-motoric hyperactivity and adventitious movements
  • Temporal relationships between group A streptococcus (GAS) infections and symptom exacerbations
  • Abrupt onset of symptoms (within 7 days) occurring in the past 4 months.
  • Confirmed diagnosis of PANS or PANDAS based on published criteria (see above).

Exclusion Criteria5

  • History of tics, OCD or food restriction/avoidance that contradicts a history of sudden onset or was present before the onset of this investigation
  • Current symptom(s) of Pica
  • Previous participation in the study
  • Not suitable for study participation at the discretion of the site investigator (e.g., the child does not have verbal or cognitive ability adequate for self-report assessment)
  • Patient or family is unable to complete the study questionnaires or procedures in English as the primary language

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(2)

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

UW School of Medicine and Public Health

Madison, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06811935


Related Trials